Health technology management: the experience of a managed access approach to the reimbursement of dupilumab in Ireland. Barrett R, Barry M, McCullagh L. Ir J Med Sci. 2023 May 9. doi: 10.1007/s11845-023-03378-7.
Clinical expert opinion to inform Health Technology Assessments. O’Callaghan J, Tilson L, Fogarty E, McCullagh L. Ir Med J; September 2023; Vol 116; No. 8; P826 Clinical expert opinion to inform Health Technology Assessment – Irish Medical Journal (imj.ie)
A comparison of relative-efficacy estimate(s) derived from both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons. Cassidy O, Harte M, Trela-Larsen L, Walsh C, White A, McCullagh L, Leahy J., Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2023, pS1098-3015(23)03061-9 Journal Article, 2023 DOI
The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries’ past health technology assessments. Vreman RA, van Hoof D, Nachtnebel A, Daems J, van de Casteele M, Fogarty E, Adams R, Timmers L. International Journal of Technology Assessment in Health Care, 39(1), e44, 1–7 DOI
Adverse drug reactions in an ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients. Cahir C, Curran C, Walsh C, Hickey A, Brannigan R, Kirke C, Williams D, Bennett K. Front. Pharmacol., 13 (2023). https://doi.org/10.3389/fphar.2022.1029067
The effectiveness and cost of integrating pharmacists within general practice to optimize prescribing and health outcomes in primary care patients with polypharmacy: a systematic review. Croke, A., Cardwell, K., Clyne B, Moriarty F, McCullagh L, Smith S M. BMC Prim. Care 24, 41 (2023). https://doi.org/10.1186/s12875-022-01952-z
Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting. Carey N, Leahy J, Trela-Larsen L, Mc Cullagh L & Barry M (2023) Journal of Market Access & Health Policy, 11:1, DOI: 10.1080/20016689.2023.2166375
Neoadjuvant treatment for stage III and IV cutaneous melanoma. Gorry C, McCullagh L, O’Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Cochrane Database of Systematic Reviews 2023: Issue 1. Art. No.: CD012974. DOI: http://10.1002/14651858.CD012974.pub2.
